Biomarker Testing Patterns and Treatment Outcomes in Patients With Advanced Non-Small Cell Lung Cancer and MET Exon 14 Skipping Mutations: A Descriptive Analysis From the US

BACKGROUND: MET exon 14 skipping mutation (METex14) is observed in ~3% of non-small cell lung cancer (NSCLC) cases and has been shown to be an independent poor prognostic factor associated with shorter overall disease-specific survival. Broad molecular testing can identify this biomarker in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Asad Zadeh Vosta Kolaei, Fatemeh, Cai, Beilei, Kanakamedala, Hemanth, Kim, Julia, Doban, Vitalii, Zhang, Shiyu, Shi, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915293/
https://www.ncbi.nlm.nih.gov/pubmed/35280795
http://dx.doi.org/10.3389/fonc.2022.786124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915293/
https://www.ncbi.nlm.nih.gov/pubmed/35280795
http://dx.doi.org/10.3389/fonc.2022.786124

Ejemplares similares